Afivastobart

Monoclonal antibody

Also known as AB598

Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

Also in development:Gastric Cancer · Phase 1

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1 (1)
Non-Small Cell Lung Cancer

Competitive landscape

Other CD39 (ENTPD1) drugs

IPH5201. Compare all 2 CD39 (ENTPD1) drugs

1 other tracked programme targets this mechanism, 1 of them ahead of this one.

This drug's own stage for Gastric Cancer: Phase 1. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Afivastobart: this drugPhase 1Monoclonal antibodyCD39 (ENTPD1)not yet gradedNo reviewed efficacy summary in this indication
Capecitabine
ApprovedUS marketing discontinued
Small moleculeFluoropyrimidine (antimetabolite)not yet gradedNo reviewed efficacy summary in this indication
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
NivolumabApprovedMonoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Reliable signalNo reviewed efficacy summary in this indication
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
RamucirumabApprovedMonoclonal antibodyVEGFR2Reliable signal
NCT01170663: Overall Survival Time (OS) (Randomization up to 27.5 months): Ramucirumab (IMC-1211B) Plus Paclitaxel 9.6 months (95% CI 8.5 to 10.8) | Placebo Plus Paclitaxel 7.4 months (95% CI 6.3 to 8.4)
NCT00917384: Overall Survival (OS) (Randomization up to 28 months post-randomization): IMC-1121B (Ramucirumab) 5.2 months (95% CI 4.4 to 5.7) | Placebo 3.8 months (95% CI 2.8 to 4.7)
TislelizumabApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
ZanidatamabApprovedMultispecific antibodyHER2not yet gradedNo reviewed efficacy summary in this indication
ASP2138Phase 3Multispecific antibodyClaudin 18.2 x CD3not yet gradedNo reviewed efficacy summary in this indication
CamrelizumabPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Disitamab VedotinPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
ONO-4578Phase 3Small moleculeProstaglandin E2 receptor 4 (EP4)Reliable signal
NCT06256328: ONO-4578-08 study (NCT06256328): median PFS 9.0 months (ONO-4578 + nivolumab + chemotherapy) vs 6.9 months (placebo + nivolumab + chemotherapy); HR 0.67, 90% CI 0.48-0.92, P=0.040.
Retlirafusp AlfaPhase 3Multispecific antibodyPD-L1 and TGF-beta (TGF-βRII trap)Partial signal
NCT04950322: Primary endpoint, overall survival vs placebo plus CAPOX: median 16.8 vs 10.4 months (HR 0.53) in PD-L1 CPS >=5 and 15.8 vs 11.2 months (HR 0.66) in the ITT set (JCO, 2026-09-24).
RilvegostomigPhase 3Multispecific antibodyPD-1 and TIGITnot yet gradedNo reviewed efficacy summary in this indication
S-1Phase 3Small moleculeThymidylate synthase (via 5-FU, released from tegafur) and dihydropyrimidine dehydrogenase (inhibited by gimeracil)not yet gradedNo reviewed efficacy summary in this indication
SerplulimabPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Sonesitatug VedotinPhase 3Antibody–drug conjugateClaudin 18.2 (CLDN18.2)not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
agenT-797Phase 2Cell therapyInvariant TCR / NKG2D ligands (tumor cell recognition), no single defined myeloma antigennot yet gradedNo reviewed efficacy summary in this indication
GivastomigPhase 2Multispecific antibodyClaudin 18.2 (CLDN18.2) x 4-1BBnot yet gradedNo reviewed efficacy summary in this indication
SHR-A1904Phase 2Antibody–drug conjugateClaudin 18.2 (CLDN18.2)not yet gradedNo reviewed efficacy summary in this indication
ASP546C
Phase 1/2(overall)
Antibody–drug conjugateClaudin 18.2 (CLDN18.2)not yet gradedNo reviewed efficacy summary in this indication
TAK-921Phase 1/2Antibody–drug conjugate—not yet gradedNo reviewed efficacy summary in this indication
CRX100Phase 1Cell therapyCell-based oncolytic virus immunotherapynot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Afivastobart to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
September 2027 (1)
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-09 · NCT05891171 · CT.gov ↗
What to watch

See the full readout calendar ↗